Key Highlights

  • LENZ Therapeutics (NASDAQ:LENZ) held USD 197.3 million of cash and marketable securities at September 30, 2026, split between USD 30.6 million of cash and USD 166.8 million of securities, per its quarterly filing.
  • Third quarter net product Revenue was USD 2.6 million and total revenue USD 3.4 million, including USD 785 thousand of license revenue, against a net loss of USD 31.0 million.
  • Net loss per share was USD 0.99 for the quarter and USD 3.33 for nine months, with 31,420,583 shares outstanding as of October 28, 2026.
  • Published market data showed USD 3.52, up 0.57%, and a one year EPS change of 112.45%; an October 23 close of USD 3.16 was also published, and bases were not confirmed.

VIZZ Revenue Is Growing From a Very Small Base

LENZ Therapeutics (NASDAQ:LENZ) is a commercial-stage eye care company whose product VIZZ is a prescription eye drop for presbyopia, the age-related loss of near vision. In its quarterly filing for the period ended September 30, 2026, it reported net product revenue of USD 2.6 million and total revenue of USD 3.4 million. The quarterly net loss was USD 31.0 million and the nine-month loss USD 104.4 million. Management said prescriptions rose more than 45% from June to July after a telehealth prescribing launch on July 6, 2026, while warning that one month does not make a trend, according to published coverage. Published coverage also cited a prescriber base above 13,000 and 27,000 packs sold in the second quarter.

A Cash Pile That Exceeds What the Market Appears to Value

The filing says existing resources are sufficient for at least 12 months and discloses no Going Concern language, though the company may need additional capital. Cash and securities of USD 197.3 million divided by 31,420,583 shares equals about USD 6.28 per share, simple arithmetic on two published numbers. That compares with quoted prices of USD 3.52 on the screen and an October 23 close of USD 3.16. Published coverage said shares were far below the 200-day Moving Average of USD 8.52 and cited concerns about stalled physician prescribing and weak retail pharmacy uptake. Cash is not the same as value, because a loss of USD 31.0 million per quarter consumes it steadily.

Reading a 112.45% EPS Change for a Loss-Making Company

The aggressive small-cap screen lists a one year EPS change of 112.45% for LENZ Therapeutics (NASDAQ:LENZ). The filing reports a GAAP net loss per share of USD 0.99 for the quarter, so any change figure is measured from a loss base, its direction and basis are unconfirmed, and it should not be read as profit growth. Published coverage cited analyst expectations of a USD 0.99 loss on about USD 4.0 million of revenue, which would put reported total revenue of USD 3.4 million below that level. Market Capitalization was not verified, and small biotech shares can move sharply on thin news.

Where Things Stand

Probably because the market doubts that sales will grow fast enough to justify the spending, not because cash is short. LENZ Therapeutics (NASDAQ:LENZ) had USD 197.3 million of cash and securities and 12 months of stated funding, about USD 6.28 per share by simple arithmetic, yet revenue is only USD 2.6 million of product sales against quarterly losses of USD 31.0 million. The next evidence is prescription trends after the telehealth launch, quarterly pack volumes and the pace of cash use. A discount to cash can persist if losses keep eroding the balance.